# EDGAR Filing Document

**Accession Number:** 0001962926
**File Stem:** 0001962926-26-000005
**Filing Date:** 2026-6
**Character Count:** 7404
**Document Hash:** 8ad86ef33735f84a2d7bb5900a45543f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001962926-26-000005.hdr.sgml**: 20260629

**ACCESSION NUMBER**: 0001962926-26-000005

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260625

**FILED AS OF DATE**: 20260629

**DATE AS OF CHANGE**: 20260629

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Lin Xichen
- **CENTRAL INDEX KEY:** 0001962926

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41608
- **FILM NUMBER:** 261137665

**MAIL ADDRESS:**
- **STREET 1:** C/O STRUCTURE THERAPEUTICS INC.
- **STREET 2:** 601 GATEWAY BLVD., SUITE 900
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Structure Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001888886
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981480821
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 601 GATEWAY BLVD SUITE 900
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 457-1978

**MAIL ADDRESS:**
- **STREET 1:** 601 GATEWAY BLVD SUITE 900
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ShouTi Inc.
- **DATE OF NAME CHANGE:** 20211019

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Lin Xichen<br><sub>(Last) (First) (Middle)</sub><br>C/O STRUCTURE THERAPEUTICS INC.<br>601 GATEWAY BLVD., SUITE 900<br><sub>(Street)</sub><br>SOUTH SAN FRANCISCO, CA 94080<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-06-25 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CHIEF SCIENTIFIC OFFICER_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Structure Therapeutics Inc. [ GPCR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 2026-06-25 |  | M |  | 23634 | A | 0.34<sup>(1)</sup> | 252594 | D |  |
| Ordinary Shares | 2026-06-25 |  | C |  | 23634<sup>(2)</sup> | D | $0 | 228960 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Share Option (right to buy) | 0.34<sup>(1)</sup> | 2026-06-25 |  | M |  |  | 23634 | <sup>(3)</sup> | 2029-09-10 | Ordinary Shares | 23634 | $0 | 190166<sup>(4)</sup> | D |  |
| American Depositary Shares | <sup>(5)</sup> | 2026-06-25 |  | C |  | 7878<sup>(6)</sup> |  | <sup>(5)</sup> | <sup>(5)</sup> | Ordinary Shares | 23634 | $0 | 7878 | D |  |
| American Depositary Shares | <sup>(5)</sup> | 2026-06-25 |  | S<sup>(7)</sup> |  |  | 7878 | <sup>(5)</sup> | <sup>(5)</sup> | Ordinary Shares | 23634 | 49.0792<sup>(8)</sup> | 0 | D |  |

---

### Footnotes:

(1) Reflects price per share in Ordinary Shares.

(2) The Ordinary Shares were converted into American Depositary Shares as reported in Table II.

(3) 1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

(4) This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 23,634 Ordinary Shares.

(5) Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer.  The American Depositary Shares have no expiration date.

(6) 23,634 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 7,878 American Depositary Shares.

(7) The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.

(8) Reflects price per share in American Depositary Shares.

**Signature:** /s/ Jun Yoon, Attorney-in-Fact  
**Date:** 2026-06-29

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**